The molecular pathogenesis of osteosarcoma: A review

Osteosarcoma is the most common primary malignancy of bone. It arises in bone during periods of rapid growth and primarily\ud affects adolescents and young adults. The 5-year survival rate for osteosarcoma is 60%–70%, with no significant improvements in\ud prognosis since the advent of multiagent chemotherapy. Diagnosis, staging, and surgical management of osteosarcoma remain\ud focused on our anatomical understanding of the disease. As our knowledge of the molecular pathogenesis of osteosarcoma\ud expands, potential therapeutic targets are being identified. A comprehensive understanding of these mechanisms is essential if\ud we are to improve the prognosis of patients with osteosarcoma through tumour-targeted therapies. This paper will outline the\ud pathogenic mechanisms of osteosarcoma oncogenesis and progression and will discuss some of the more frontline translational\ud studies performed to date in search of novel, safer, and more targeted drugs for disease management